Exchange: NASDAQ·Updated 07:30 PM EDT
MDGL logo

MDGL Madrigal Pharmaceuticals Inc

$471.75
$5.16
(1.08%)
Today
Closed $471.75
$0.00
(0.00%)
After Hours
EarningsNov 4
Mkt Cap$11.02B
Vol312,998.00

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
51

Neutral Sentiment

How do you feel about MDGL?

sarkar20
$MDGL Most of the times this kind if manipulation (without any news) is seen before BO!! Hope this is the case for MDGL too, BO soon?
1
2
balzofsteel
$MDGL The company is a potential takeover target One thing that could set the stock's price soaring is a takeover attempt by a larger pharmaceutical company. Madrigal's combination of a differentiated asset in Rezdiffra, strong cash reserves ($838.9 million as of the second quarter), and a pipeline in development makes it an attractive target for larger pharmaceutical firms seeking to enter the metabolic liver disease space. The global research and development (R&D) landscape is increasingly characterized by partnerships and acquisitions, as companies seek to fast-track access to novel therapies, a mindset that continues to accelerate biotech M&A across the healthcare sector. Rezdiffra's U.S. patent protection until 2045 and its 2025 approval in the European Union provide a durable competitive moat. A takeover would allow a larger firm to capitalize on Rezdiffra's commercial momentum while mitigating the risks of in-house R&D.
1
3
Wallst45
$MDGL CITI INITIATES MADRIGAL PHARMACEUTICALS COVERAGE WITH BUY RATING AND $725 PT The firm believes the company's Rezdiffra is being underappreciated at current share levels. The launch has exceeded expectations and "blockbuster status is imminent"
4
1986iamwallstreet
$MDGL undervalued, when that huge buyout come this will be trending and people will be saying nobody told them about this lol
4
balzofsteel
$MDGL Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725 Benzinga 2026-09-23T11:04:00-04:00 Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (MDGL.NaE) with a Buy rating and announces Price Target of $725
3
sarkar20
$MDGL I agree, I think it is in final stages, soon this beauty will get a BO!! 900 coming soon, imo!!
3
forprofit12
$MDGL and? Price is still pathetic. Regret adding this. The lost opportunity cost on this one is huge.
2
forprofit12
$MDGL volume is down as there are no near term catalysts. Wouldn’t mind a buyout though.
2
Whiskeyunderthebed
$MDGL Has nothing to do with it- sector rotation and money are leaving health care sector-
1
Live2ride
$MDGL Getting close to another swing trade. MDGL.... come on downnnnnnn. Your the next contestant on the Price is Right.
1
sarkar20
$MDGL I guess there is no BO and it seems not good things in future the way stock price is moving these days!!

Advertisement|Remove ads.